<DOC>
	<DOC>NCT00122317</DOC>
	<brief_summary>The purpose of this study is to evaluate the long-term safety of eculizumab in patients with transfusion dependent hemolytic PNH.</brief_summary>
	<brief_title>Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)</brief_title>
	<detailed_description />
	<mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<criteria>Patients who have fully completed the TRIUMPH, SHEPHERD, or X03001 studies TRIUMPH patients who have discontinued receiving investigational drug prior to the last visit of the study due to lack of efficacy or exacerbation of symptoms of PNH and have completed all monthly safety and efficacy procedures Patient must be willing and able to give written informed consent Patient must avoid conception during the trial Patients who have terminated early from the SHEPHERD or X03001 studies Patients who have terminated early from the TRIUMPH study due to an adverse event Female who is pregnant, breast feeding, or intending to conceive during the course of the study Any condition that could increase the patient's risk by participating in the study or could confound the outcome of the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Transfusion dependent, hemolytic paroxysmal nocturnal hemoglobinuria</keyword>
</DOC>